Trocoxil

RSS

mavacoxib

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 05/05/2020

Authorisation details

Product details
Name
Trocoxil
Agency product number
EMEA/V/C/000132
Active substance
mavacoxib
International non-proprietary name (INN) or common name
mavacoxib
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QM01AH92
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Revision
10
Date of issue of marketing authorisation valid throughout the European Union
09/09/2008
Contact address

Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Product information

29/04/2020 Trocoxil - EMEA/V/C/000132 - IB/0020

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Not yet assigned

Therapeutic indication

For the treatment of pain and inflammation associated with degenerative joint disease in dogs in cases where continuous treatment exceeding one month is indicated.

Assessment history

How useful was this page?

Add your rating
Average
1 rating